Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibitor, for the treatment of HCC.

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma

- Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins –

Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022

EDISON, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today urged its stockholders to vote “FOR” all proposals put forth in the definitive proxy statement prior to its June 24, 2022 Annual Meeting of Stockholders.

Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we've been informed by the company that in both the headline and first paragraph the name 'Recofilstat' should be 'Rencofilstat'. Completed corrected text follows.

CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc.

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announces that its Chief Medical Officer, Todd Hobbs, MD, gave a clinical presentation entitled “Recofilstat (CRV431): A liver-targeting drug candidate for NASH and HCC” today at the 5th Global NASH Congress.

Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress

- HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes -

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

Here is how Hepion Pharmaceuticals, Inc. (HEPA) and ICU Medical (ICUI) have performed compared to their sector so far this year.

Is Hepion Pharmaceuticals, Inc. (HEPA) Stock Outpacing Its Medical Peers This Year?

Here is how Hepion Pharmaceuticals, Inc. (HEPA) and BioDelivery Sciences International (BDSI) have performed compared to their sector so far this year.

Has Hepion Pharmaceuticals, Inc. (HEPA) Outpaced Other Medical Stocks This Year?

- Dr. Cheung, who has dedicated his career to NASH, hepatocellular carcinoma, fatty liver disease, and viral hepatitis will endeavor to advance Hepion's business development and partnering efforts in Asia -

Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company's Strategic Medical Affairs in Asia

Anti-tumor activity observed in fatty livers suggests rencofilstat may increase the treatment potential of anti-PD1 treatment in human liver cancer Anti-tumor activity observed in fatty livers suggests rencofilstat may increase the treatment potential of anti-PD1 treatment in human liver cancer

Hepion Pharmaceuticals' Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study

Hepion begins the crucial year 2022, where it will finally be determined whether CRV431 possesses anti-fibrotic/anti-inflammatory activity in NASH patients. In the case of positive data (Fibroscan, ELF score, etc.), it would not be strange to see revaluations in the share prices of x3 or even x4.

Hepion Pharmaceuticals: Facing The Momentous Year 2022

EDISON, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced the United States Adopted Names (“USAN”) Council has adopted the nonproprietary name “rencofilstat” for the Company's lead drug candidate, CRV431.

Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431

EDISON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced that it will participate in the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022.

Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference

- Oral Presentation Chosen as a “Distinguished” Abstract - - Oral Presentation Chosen as a “Distinguished” Abstract -

Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference

- New IND Expands Liver Disease Pipeline for CRV431 -

Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer

EDISON, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced the results of a nonclinical research study showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. Additionally, CRV431 was as effective at decreasing tumor burden as an anti-PD1 antibody immune checkpoint inhibitor, PD1 antibody, and produced more beneficial changes in tumor infiltrating cells compared to anti-PD1 antibody treatment.

Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study

EDISON, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and other liver diseases, today announced that results from a study conducted by Dr. Philippe Gallay's research group at The Scripps Research Institute examining the anti-tumor mechanism of the Company's lead drug candidate, CRV431, will be available as an e-poster at the Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), to be held virtually November 12-15, 2021.

Anti-Cancer Mechanism of Hepion Pharmaceuticals' CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021

The stock price of Hepion Pharmaceuticals Inc (NASDAQ: HEPA) increased by over 7% during intraday trading today. This is why it happened.

HEPA Stock: Why It Increased Today

EDISON, N.J., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced results from a Drug-Drug Interaction (‘DDI') study with its lead drug candidate, CRV431.

All Endpoints Met in Hepion Pharmaceuticals' Drug-Drug Interaction Study with CRV431

On September 13, Hepion Pharmaceuticals (NASDAQ:HEPA) reported additional data from phase IIa "AMBITION trial."

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced additional efficacy data from its Phase 2a AMBITION clinical trial. Related Content:   Hepion Pharma's NASH Candidate Aces Mid-Stage Study.

Hepion Pharma Shares Encouraging Biomarker Data From NASH Trial

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis (NASH) trial. Today, Hepion will share additional data from the Phase 2a AMBITION trial, evaluating CRV431, a potent inhibitor of cyclophilins involved in many disease processes.

Why Are Hepion Pharma Shares Moving Higher Premarket Monday?

EDISON, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and liver disease, today announced that it expects to release additional data from its Phase 2a ‘AMBITION' NASH clinical trial before the market opens on Monday, September 13, 2021. As previously disclosed, all primary endpoints were achieved in the trial.

Hepion Pharmaceuticals Schedules Conference Call to Review Data from Phase 2a ‘AMBITION' Clinical Trial of CRV431 in NASH

Leap Therapeutics

Nymox Pharmaceutical

Verastem

These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%

Hepion Pharmaceuticals is a promising candidate in the race for an effective drug for treating NASH. Although still in a very early phase of trials, CRV431 has presented very promising preclinical results.

News for Hepion Pharmaceuticals Inc Stock (HEPA)